The use of generic drugs is increasing in our country.
Covering around 28 percent of total drug consumption, the generic market in Italy is expanding, albeit more cautiously than the trends in other European countries. Of the almost 600 registrations activated at the moment, about 30 percent date back to this last year. The opportunity to talk about it was promoted last April by Tad Pharma, a specialist in generics, born in Germany in 1968 and now also present in Italy. On the other hand, the subject is topical again due to the expiry of the patent on several molecules, among which those commonly used for the treatment of chronic pathologies stand out. Not to mention the emergence of new possibilities in the management of patients paid for by the National Health Service, so much so that in Germany, according to the data presented, the generic market (established itself earlier than in our country) currently constitutes around 48 per cent of expenditure public health. In fact, it is not so much research that interests those dedicated to producing generics, as large-scale production, understood as the preparation of chemotherapy drugs, due to their high cost, but above all as the distribution of large volumes of drugs for the treatment of chronic diseases. In Germany, this type of policy has already allowed for savings in public health expenditure and, recently, also the launch of a project which aims to reduce the errors that elderly patients, or patients suffering from multiple pathologies, can make in taking multiple concomitant treatments. And also in Germany, as already in Sweden, the production of personalized blister packs has started, designed to contain all the medicines together (where possible, of the generic type) to be taken at the same time.
Covering around 28 percent of total drug consumption, the generic market in Italy is expanding, albeit more cautiously than the trends in other European countries. Of the almost 600 registrations activated at the moment, about 30 percent date back to this last year. The opportunity to talk about it was promoted last April by Tad Pharma, a specialist in generics, born in Germany in 1968 and now also present in Italy. On the other hand, the subject is topical again due to the expiry of the patent on several molecules, among which those commonly used for the treatment of chronic pathologies stand out. Not to mention the emergence of new possibilities in the management of patients paid for by the National Health Service, so much so that in Germany, according to the data presented, the generic market (established itself earlier than in our country) currently constitutes around 48 per cent of expenditure public health. In fact, it is not so much research that interests those dedicated to producing generics, as large-scale production, understood as the preparation of chemotherapy drugs, due to their high cost, but above all as the distribution of large volumes of drugs for the treatment of chronic diseases. In Germany, this type of policy has already allowed for savings in public health expenditure and, recently, also the launch of a project which aims to reduce the errors that elderly patients, or patients suffering from multiple pathologies, can make in taking multiple concomitant treatments. And also in Germany, as already in Sweden, the production of personalized blister packs has started, designed to contain all the medicines together (where possible, of the generic type) to be taken at the same time.
